Gunma, Japan

Yukiko Aono

USPTO Granted Patents = 3 


 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2011-2019

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):

Title: The Innovative Contributions of Yukiko Aono

Introduction

Yukiko Aono is a prominent inventor based in Gunma, Japan. She has made significant contributions to the field of biotechnology, particularly in the development of therapeutic antibodies. With a total of 3 patents to her name, Aono's work has the potential to impact medical treatments significantly.

Latest Patents

Among her latest patents is the development of an Anti FGF23 antibody and a pharmaceutical composition comprising the same. This invention aims to provide an antibody against FGF23, which can serve as a preventive or therapeutic agent by suppressing the action of FGF23. The antibody or its functional fragment against human FGF23 is produced by hybridoma C10 (Accession No. FERM BP-10772). This innovative approach could lead to new treatments for conditions related to FGF23.

Career Highlights

Yukiko Aono has worked with notable companies in the biotechnology sector, including Kyowa Hakko Kirin Co., Limited and Kyowa Kirin Co., Ltd. Her experience in these organizations has allowed her to hone her skills and contribute to groundbreaking research and development in her field.

Collaborations

Throughout her career, Aono has collaborated with esteemed colleagues such as Yuji Yamazaki and Itaru Urakawa. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Yukiko Aono's contributions to biotechnology, particularly through her patents and collaborations, highlight her role as a leading inventor in her field. Her work continues to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…